| Title |
New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer’s Disease
|
|---|---|
| Published in |
Metabolic Brain Disease, April 2018
|
| DOI | 10.1007/s11011-018-0227-1 |
| Pubmed ID | |
| Authors |
Kai Long Zhong, Fang Chen, Hao Hong, Xuan Ke, Yang Ge Lv, Su Su Tang, Yu Bing Zhu |
| Abstract |
Mounting evidence suggests that diabetes mellitus (DM) is associated with mild cognitive impairment (MCI), vascular dementia and Alzheimer's disease (AD). Biological, clinical and epidemiological data support a close link between DM and AD. Increasingly, studies have found that several antidiabetic agents can promote neurogenesis, and clinically ameliorate cognitive and memory impairments in different clinical settings. Data has shown that these antidiabetic drugs positively affect mitochondrial and synaptic function, neuroinflammation, and brain metabolism. Evidence to date strongly suggests that these antidiabetic drugs could be developed as disease-modifying therapies for MCI and AD in patients with and without diabetes. |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 60 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 15% |
| Student > Ph. D. Student | 9 | 15% |
| Student > Bachelor | 4 | 7% |
| Other | 4 | 7% |
| Researcher | 4 | 7% |
| Other | 9 | 15% |
| Unknown | 21 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 12% |
| Biochemistry, Genetics and Molecular Biology | 7 | 12% |
| Neuroscience | 5 | 8% |
| Psychology | 2 | 3% |
| Other | 2 | 3% |
| Unknown | 26 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 April 2018.
All research outputs
#4,229,660
of 23,043,346 outputs
Outputs from Metabolic Brain Disease
#175
of 1,062 outputs
Outputs of similar age
#84,066
of 329,529 outputs
Outputs of similar age from Metabolic Brain Disease
#5
of 30 outputs
Altmetric has tracked 23,043,346 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,062 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,529 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.